vs

Side-by-side financial comparison of IDT CORP (IDT) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

IDT CORP is the larger business by last-quarter revenue ($322.8M vs $207.3M, roughly 1.6× Ultragenyx Pharmaceutical Inc.). IDT CORP runs the higher net margin — 6.9% vs -62.0%, a 68.9% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 4.3%). IDT CORP produced more free cash flow last quarter ($-16.0M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 4.4%).

IDT Corporation is a multinational provider of cloud communications, point of sale systems, unified communications, and financial services foreign exchange services for selected clients. It has units dedicated for businesses and consumers such as the Boss Revolution pre-paid phone cards, headquartered in Newark, New Jersey.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

IDT vs RARE — Head-to-Head

Bigger by revenue
IDT
IDT
1.6× larger
IDT
$322.8M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+21.6% gap
RARE
25.9%
4.3%
IDT
Higher net margin
IDT
IDT
68.9% more per $
IDT
6.9%
-62.0%
RARE
More free cash flow
IDT
IDT
$84.8M more FCF
IDT
$-16.0M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
4.4%
IDT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
IDT
IDT
RARE
RARE
Revenue
$322.8M
$207.3M
Net Profit
$22.4M
$-128.6M
Gross Margin
36.6%
Operating Margin
9.6%
-54.7%
Net Margin
6.9%
-62.0%
Revenue YoY
4.3%
25.9%
Net Profit YoY
29.6%
3.5%
EPS (diluted)
$0.89
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IDT
IDT
RARE
RARE
Q4 25
$322.8M
$207.3M
Q3 25
$316.6M
$159.9M
Q2 25
$302.0M
$166.5M
Q1 25
$303.3M
$139.3M
Q4 24
$309.6M
$164.6M
Q3 24
$308.8M
$139.5M
Q2 24
$299.6M
$147.0M
Q1 24
$296.1M
$108.8M
Net Profit
IDT
IDT
RARE
RARE
Q4 25
$22.4M
$-128.6M
Q3 25
$16.9M
$-180.4M
Q2 25
$21.7M
$-115.0M
Q1 25
$20.3M
$-151.1M
Q4 24
$17.2M
$-133.2M
Q3 24
$36.8M
$-133.5M
Q2 24
$5.6M
$-131.6M
Q1 24
$14.4M
$-170.7M
Gross Margin
IDT
IDT
RARE
RARE
Q4 25
36.6%
Q3 25
36.2%
Q2 25
37.1%
Q1 25
37.0%
Q4 24
34.8%
Q3 24
33.1%
Q2 24
32.4%
Q1 24
32.7%
Operating Margin
IDT
IDT
RARE
RARE
Q4 25
9.6%
-54.7%
Q3 25
6.9%
-106.9%
Q2 25
8.8%
-64.8%
Q1 25
9.3%
-102.6%
Q4 24
7.6%
-74.3%
Q3 24
6.5%
-94.6%
Q2 24
3.8%
-79.1%
Q1 24
5.4%
-151.9%
Net Margin
IDT
IDT
RARE
RARE
Q4 25
6.9%
-62.0%
Q3 25
5.3%
-112.8%
Q2 25
7.2%
-69.0%
Q1 25
6.7%
-108.5%
Q4 24
5.6%
-80.9%
Q3 24
11.9%
-95.7%
Q2 24
1.9%
-89.5%
Q1 24
4.9%
-156.8%
EPS (diluted)
IDT
IDT
RARE
RARE
Q4 25
$0.89
$-1.28
Q3 25
$0.67
$-1.81
Q2 25
$0.86
$-1.17
Q1 25
$0.80
$-1.57
Q4 24
$0.68
$-1.34
Q3 24
$1.45
$-1.40
Q2 24
$0.22
$-1.52
Q1 24
$0.57
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IDT
IDT
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$189.3M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$320.7M
$-80.0M
Total Assets
$654.9M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IDT
IDT
RARE
RARE
Q4 25
$189.3M
$421.0M
Q3 25
$226.5M
$202.5M
Q2 25
$199.9M
$176.3M
Q1 25
$142.2M
$127.1M
Q4 24
$148.0M
$174.0M
Q3 24
$164.6M
$150.6M
Q2 24
$139.8M
$480.7M
Q1 24
$141.1M
$112.3M
Stockholders' Equity
IDT
IDT
RARE
RARE
Q4 25
$320.7M
$-80.0M
Q3 25
$305.1M
$9.2M
Q2 25
$286.2M
$151.3M
Q1 25
$271.6M
$144.2M
Q4 24
$260.6M
$255.0M
Q3 24
$246.2M
$346.8M
Q2 24
$214.5M
$432.4M
Q1 24
$211.8M
$140.3M
Total Assets
IDT
IDT
RARE
RARE
Q4 25
$654.9M
$1.5B
Q3 25
$626.2M
$1.2B
Q2 25
$600.9M
$1.3B
Q1 25
$575.7M
$1.3B
Q4 24
$554.6M
$1.5B
Q3 24
$550.1M
$1.5B
Q2 24
$517.3M
$1.6B
Q1 24
$521.8M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IDT
IDT
RARE
RARE
Operating Cash FlowLast quarter
$-10.1M
$-99.8M
Free Cash FlowOCF − Capex
$-16.0M
$-100.8M
FCF MarginFCF / Revenue
-4.9%
-48.6%
Capex IntensityCapex / Revenue
1.8%
0.5%
Cash ConversionOCF / Net Profit
-0.45×
TTM Free Cash FlowTrailing 4 quarters
$95.4M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IDT
IDT
RARE
RARE
Q4 25
$-10.1M
$-99.8M
Q3 25
$31.0M
$-91.4M
Q2 25
$75.7M
$-108.3M
Q1 25
$20.2M
$-166.5M
Q4 24
$164.0K
$-79.3M
Q3 24
$25.4M
$-67.0M
Q2 24
$9.5M
$-77.0M
Q1 24
$28.4M
$-190.7M
Free Cash Flow
IDT
IDT
RARE
RARE
Q4 25
$-16.0M
$-100.8M
Q3 25
$25.7M
$-92.7M
Q2 25
$70.3M
$-110.7M
Q1 25
$15.3M
$-167.8M
Q4 24
$-5.1M
$-79.5M
Q3 24
$20.1M
$-68.6M
Q2 24
$4.7M
$-79.0M
Q1 24
$23.9M
$-193.9M
FCF Margin
IDT
IDT
RARE
RARE
Q4 25
-4.9%
-48.6%
Q3 25
8.1%
-58.0%
Q2 25
23.3%
-66.5%
Q1 25
5.1%
-120.5%
Q4 24
-1.7%
-48.3%
Q3 24
6.5%
-49.2%
Q2 24
1.6%
-53.7%
Q1 24
8.1%
-178.2%
Capex Intensity
IDT
IDT
RARE
RARE
Q4 25
1.8%
0.5%
Q3 25
1.7%
0.8%
Q2 25
1.8%
1.5%
Q1 25
1.6%
1.0%
Q4 24
1.7%
0.1%
Q3 24
1.7%
1.2%
Q2 24
1.6%
1.4%
Q1 24
1.5%
3.0%
Cash Conversion
IDT
IDT
RARE
RARE
Q4 25
-0.45×
Q3 25
1.84×
Q2 25
3.49×
Q1 25
0.99×
Q4 24
0.01×
Q3 24
0.69×
Q2 24
1.71×
Q1 24
1.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IDT
IDT

IDT Digital Payments$104.4M32%
IDT Global$60.2M19%
BOSS Revolution$45.7M14%
National Retail Solutions$39.3M12%
BOSS Revolution Money Transfer$36.3M11%
Net2phone$23.9M7%
Other$8.0M2%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons